Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24010856 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Nadia Hindi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, HMGB1 Protein, Rhabdomyosarcoma, Embryonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IVAN PEREZ, National Institute of Health Carlos III.
Abstract (Originalsprache)
Rhabdomyosarcoma (RMS) in adults is a rare and aggressive disease, which lacks standard therapies for relapsed or advanced disease. This retrospective study aimed to describe the activity of BOMP-EPI (bleomycin, vincristine, methotrexate and cisplatin alternating with etoposide, cisplatin and ifosfamide), an alternative platinum-based regimen, in adult patients with relapsed/metastatic RMS. In the study, 10 patients with RMS with a median age at diagnosis of 20.8 years and a female/male distribution of 6/4 received a mean of 2.5 cycles of BOMP-EPI. The best RECIST response was a complete response in 1/10 (10%) patients, a partial response in 5/10 (50%), stable disease in 3/10 (30%) and progression in 1/10 (10%). With a median follow-up in the alive patients from the start of therapy of 30.5 months (15.7–258), all patients progressed with a median progression-free survival of 8.47 months (95% CI 8.1–8.8), and 7/10 patients died with a median overall survival of 24.7 months (95% CI 13.7–35.6). BOMP-EPI was an active chemotherapy regimen in adults with pediatric-type metastatic RMS, with outcomes in terms of survival that seem superior to what was expected for this poor-prognosis population. Low HMGB1 expression level was identified as a predictive factor of better response to this treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), 28040 Madrid, Spain.
- Medical Oncology Department, University Hospital General de Villalba, 28400 Madrid, Spain.
- Medical Oncology Department, University Hospital Fundación Jiménez Díaz, 28040 Madrid, Spain.
- Institute of Biomedicine of Seville (IBIS), HUVR-CSIC-University of Seville, 41013 Seville, Spain.
- CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Medical Oncology Department, University Hospital Son Espases, 07210 Palma, Spain.
ORCID-Profile: Nadia Hindi, José Durán, Javier Martín-Broto
Förderung
- IVAN PEREZ
- National Institute of Health Carlos III
Zitieren
APA
Hindi, N., Carrillo-García, J., Blanco-Alcaina, E., Renshaw, M., Luna, P., Durán, J., Jiménez, N., Sancho, P., Ramos, R., Moura, D. S., & Martín-Broto, J. (2023). Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24010856
Vancouver
Hindi N, Carrillo-García J, Blanco-Alcaina E, Renshaw M, Luna P, Durán J, et al. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24010856
BibTeX
@article{Hindi2023,
author = {Hindi, Nadia and Carrillo-García, Jaime and Blanco-Alcaina, Elena and Renshaw, Marta and Luna, Pablo and Durán, José and Jiménez, Natalia and Sancho, Pilar and Ramos, Rafael and Moura, David S and Martín-Broto, Javier},
title = {Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24010856}
}
EUVIMED